CN1911277A - Medicine for treating leukopenia - Google Patents
Medicine for treating leukopenia Download PDFInfo
- Publication number
- CN1911277A CN1911277A CN 200610127908 CN200610127908A CN1911277A CN 1911277 A CN1911277 A CN 1911277A CN 200610127908 CN200610127908 CN 200610127908 CN 200610127908 A CN200610127908 A CN 200610127908A CN 1911277 A CN1911277 A CN 1911277A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine
- medicine extract
- group
- berbamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A Chinese medicine for treating leukocytopenia and promoting the reproduction of white cells contains berbamine and the extracts of Chinese-medicinal materials.
Description
Invention field
This invention relates to the treatment disease in the blood system, the Integrative Chinese-Western medicine of leukopenia and agranulocytosis.
Background technology
Leukopenia and agranulocytosis are internal medicine blood system commonly encountered diseases, frequently-occurring disease, and its pathogenic factor can or infect and other disease causes because of chemical factors such as medicine (as benzolism), and partly cause is not clear.Particularly in the therapeutic process of many tumor diseases, need to use chemotherapy or actinotherapy treatment mostly, these two kinds of therapies all can be killed and wounded human leukocytes in a large number, it is the important pathogenesis of primary disease, many tumour patients often can not continue to accept chemotherapy or radiotherapy because of leukopenia causes, so that lose the therapy apparatus meeting, cause the development and the deterioration of tumor.Therefore, the treatment primary disease is particularly treated the leukopenia problem in tumour patient radiotherapy, the chemotherapy process, becomes the key subjects of domestic and international medical circle.
Though modern medicine has had deep understanding for the cause of disease, but in treatment, still lack new means, Therapeutic Method does not have major progress in recent years, generally adopts group vitamins leukocyte increasing (as adenine phosphate), colony stimulating factor and use adrenocortical hormone to reduce the leukocyte that causes because of immunity to destroy.These therapies, curative effect is unsatisfactory, and with some serious adverse comparatively, has limited the clinical scope of application.
The traditional Chinese medical herbal treatment primary disease, general employing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, vigorate qi and replenish the blood, grow methods such as anti-tonifying YANG, though some patient is had curative effect preferably, but it is cumbersome with decocting for Chinese herbal medicine, dose is excessive and the time is long, how can influence disadvantages such as appetite, it is very few that the clinical application that has limited tumour patient serves as based on the leukocyte increasing of Chinese medicine to raise variety in the existing market of Chinese medicine preparation of main effect, and generally be compound preparation, and flavour of a drug are many, curative effect is extensively and not special, and especially the effect of leukocyte increasing is slowly and not remarkable.
The objective of the invention is to, the medicine that provides a kind of Chinese medicine and western medicine to unite use, Chinese medicine and Western medicine can be brought into play synergism, reduce the side effect of Western medicine on the one hand, onset rapidly on the other hand.This medicine can be used for various acute and chronic leukopenias or agranulocytosis, is particularly useful for because of the above-mentioned disease due to tumor disease radiotherapy or the chemotherapy.In leukocyte increasing, there is not the toxic and side effects of other similar Western medicine, it is also few that degradation reacts under the appetite due to other Chinese medicine because of taking.
Summary of the invention
This invention compositions realizes as follows: by weight
94 parts of 1 part of Chinese medicine extract of berbamine
Wherein Chinese medicine extract prepares according to the method for putting down in writing in the Chinese patent CN1058908A description: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soaked in the molten device 7-10 hour.Decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire be concentrated into 1: 1 (g: ml) elimination insoluble matter, add 95% ethanol to pure content 80%, left standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation promotion leucocyte hyperplasia.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has the effect that promotes leucocyte hyperplasia more by force, i.e. leukogenic effect.
Cyclophosphamide 120mg/kg/ day is injected in healthy Kunming mouse abdominal cavity continuously, continuous three days, treat that peripheral blood kind leukocyte reduces to 1000/mm
3After, begin to take and respectively organize medicine, set up leukopenia model after the mice chemotherapy, carry out the pharmacodynamics test that Pharmaceutical composition of the present invention promotes leucocyte hyperplasia.Each is organized medicine and used 7 days continuously, irritates stomach every day 1 time, 10 of every group of mices.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.94g/kg body weight as indicated above
3 berbamine groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight berbamine+extractum 0.94g/kg body weight mentioned above is irritated stomach.
| Group | The leukocyte number |
| Group 1 | 1012±108.2/mm 3 |
| Group 2 | 1937±111.4/mm 3 |
| Group 3 | 2201±180.5/mm 3 |
| Group 4 | 3035±194.1/mm 3 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, berbamine group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and berbamine group.Show that there are cooperative effect in berbamine and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio berbamine and Chinese medicine extract mentioned above at 1: 94.
Can produce the capsule that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio berbamine and Chinese medicine extract mentioned above at 1: 94.
Claims (2)
1 one kinds of compositionss that promote leucocyte hyperplasia, it comprises by weight
94 parts of 1 part of Chinese medicine extract of berbamine
Wherein Chinese medicine extract prepares according to following method: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soaked in the molten device 7-10 hour.Decoct with water respectively then three times, the time was respectively 1.5,1,0.5 hours, and three fried liquid are merged, and slow fire concentrates, the elimination insoluble matter adds 95% ethanol to pure content 80%, leaves standstill 12 hours, filters, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
The purposes of 2 compositionss as claimed in claim 1 in the medicine of preparation promotion leucocyte hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101279084A CN100425252C (en) | 2006-09-01 | 2006-09-01 | Medicine for treating leukopenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101279084A CN100425252C (en) | 2006-09-01 | 2006-09-01 | Medicine for treating leukopenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1911277A true CN1911277A (en) | 2007-02-14 |
| CN100425252C CN100425252C (en) | 2008-10-15 |
Family
ID=37720440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101279084A Expired - Fee Related CN100425252C (en) | 2006-09-01 | 2006-09-01 | Medicine for treating leukopenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100425252C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780142A (en) * | 2010-03-17 | 2010-07-21 | 张大宇 | Leukogenic medicament containing lithium carbonate |
| WO2013026373A1 (en) * | 2011-08-19 | 2013-02-28 | 杭州本生药业有限公司 | Use of berbamine for treating chronic myeloid leukemia |
| CN103169796A (en) * | 2011-12-20 | 2013-06-26 | 王佳丽 | Medicine for treating agranulocytosis with fungal infection of blood disease patients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058908A (en) * | 1990-08-15 | 1992-02-26 | 于宗亮 | Prescription of oral liquor for increasing leucocyte and manufacturing process |
-
2006
- 2006-09-01 CN CNB2006101279084A patent/CN100425252C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780142A (en) * | 2010-03-17 | 2010-07-21 | 张大宇 | Leukogenic medicament containing lithium carbonate |
| CN101780142B (en) * | 2010-03-17 | 2011-09-14 | 宁波市鄞州昌达生物科技有限公司 | Leukogenic medicament containing lithium carbonate |
| WO2013026373A1 (en) * | 2011-08-19 | 2013-02-28 | 杭州本生药业有限公司 | Use of berbamine for treating chronic myeloid leukemia |
| CN103169796A (en) * | 2011-12-20 | 2013-06-26 | 王佳丽 | Medicine for treating agranulocytosis with fungal infection of blood disease patients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100425252C (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN100441205C (en) | Medicine for treating blood system disease | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN100443092C (en) | Granulocyte raised drug comprising cepharanthine | |
| CN100381163C (en) | Medicine comprising rilmenidine | |
| CN103223149A (en) | Chinese herb medicine composition for treating lung cancer | |
| CN101439089B (en) | Medicament containing oxymatrine | |
| CN101773660B (en) | Medicament containing anubi-polypeotide | |
| CN101780142B (en) | Leukogenic medicament containing lithium carbonate | |
| CN101732688B (en) | Amlodipine-containing medicament | |
| CN1723956A (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1052419C (en) | Herb medicine for treating diabetes mellitus | |
| CN1246027C (en) | Medicine for treating high blood pressure and its preparation method | |
| CN115531459B (en) | Application of Jingfeng particles in preparing medicament for preventing or treating myocardial infarction | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN100367959C (en) | Medicine contg. irbesartan | |
| CN100367956C (en) | Medicine for treating hypertension | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1162174C (en) | Medicine for treating diabetes | |
| CN105232703B (en) | A kind of Chinese medicine composition and its preparation method and application for treating cervical spondylotic myelopathy | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN115154528A (en) | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia | |
| CN116688001A (en) | Traditional Chinese medicine composition for preventing and treating tumor bone metastasis and reducing osteoporosis and/or toxic and side effects of chemotherapy, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ma Hongsen Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081015 |